Corbadrine

Corbadrine
Clinical data
Trade names	Neo-Cobefrine
Other names	Levonordefrin; α-Methylnorepinephrine; (–)-3,4-Dihydroxynorephedrine; 3,4,β-Trihydroxy-α-methylphenethylamine; 3,4,β-Trihydroxyamphetamine
ATC code	None;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol;
CAS Number	829-74-3 ;
PubChem CID	164739;
IUPHAR/BPS	508;
DrugBank	DB06707 ;
ChemSpider	144416 ;
UNII	V008L6478D;
KEGG	D02388 ;
ChEMBL	ChEMBL677 ;
CompTox Dashboard (EPA)	DTXSID6046349 ;
ECHA InfoCard	100.113.606
Chemical and physical data
Formula	C9H13NO3
Molar mass	183.207 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1ccc(cc1O)[C@@H](O)[C@@H](N)C;
	InChI InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1 ; Key:GEFQWZLICWMTKF-CDUCUWFYSA-N ;
	(verify)

Corbadrine, sold under the brand name Neo-Cobefrine and also known as levonordefrin and α-methylnorepinephrine, is a catecholamine sympathomimetic used as a topical nasal decongestant and vasoconstrictor in dentistry in the United States. It is usually used in a pre-mixed solution with local anesthetics, such as mepivacaine.

The drug acts as a non-selective agonist of the α₁-, α₂-, and β-adrenergic receptors. It is said to have preferential activity at the α₂-adrenergic receptor.

Corbadrine is also a metabolite of the antihypertensive drug methyldopa and plays a role in its pharmacology and effects.